CD4 and cancer: Another phase 2 trial in advanced urothelial carcinoma certified that cabozantinib, a multikinase inhibitor, could also be a new therapeutic option for these cancer patients by lowering the percentage of Tregs among CD4+ T cells and the G-MDSC populations [190].